Sodium-glucose cotransporter 2 inhibitor versus metformin as first-line therapy in patients with type 2 diabetes mellitus: a multi-institution database study

BACKGROUND: Sodium-glucose co-transporter 2 inhibitors (SGLT2i) has shown evidence of cardiovascular benefit in patients with type 2 diabetes mellitus (T2DM). Currently metformin is the guideline-recommended first-line treatment. We aimed to investigate the benefit of SGLT2i vs metformin as first-li...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Tien-Hsing, Li, Yan-Rong, Chen, Shao-Wei, Lin, Yu-Sheng, Sun, Chi-Chin, Chen, Dong-Yi, Mao, Chun-Tai, Wu, Michael, Chang, Chih-Hsiang, Chu, Pao-Hsien, Wu, Victor Chien-Chia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7654060/
https://www.ncbi.nlm.nih.gov/pubmed/33167990
http://dx.doi.org/10.1186/s12933-020-01169-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7654060/
https://www.ncbi.nlm.nih.gov/pubmed/33167990
http://dx.doi.org/10.1186/s12933-020-01169-3

Ejemplares similares